PE20191077A1 - Esteres de oxaborol y sus usos - Google Patents

Esteres de oxaborol y sus usos

Info

Publication number
PE20191077A1
PE20191077A1 PE2019000887A PE2019000887A PE20191077A1 PE 20191077 A1 PE20191077 A1 PE 20191077A1 PE 2019000887 A PE2019000887 A PE 2019000887A PE 2019000887 A PE2019000887 A PE 2019000887A PE 20191077 A1 PE20191077 A1 PE 20191077A1
Authority
PE
Peru
Prior art keywords
oxaborol
methyl
valinate
dihydrobenzo
carbonyl
Prior art date
Application number
PE2019000887A
Other languages
English (en)
Inventor
Tsutomu Akama
David Scott Carter
Jason S Halladay
Robert T Jacobs
Yang Liu
Jacob J Plattner
Yong-Kang Zhang
Michael John Witty
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of PE20191077A1 publication Critical patent/PE20191077A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se refiere a compuestos de ester de oxaborol tales como (6-(trifluorometil)piridina-3-il)metil(1-hidroxi-7-metil-1,3-dihidrobenzo[c] [1,2]oxaborol-6-carbonilo)-L-valinato; 4-fluorobencil(1-hidroxi-7-metil-1,3-dihidrobenzo[c] [1,2]oxaborol-6-carbonilo)-L-valinato; 4,4-difluorociclohexil(1-hidroxi-7-metil-1,3-dihidrobenzo[c] [1,2]oxaborol-6-carbonilo)-L-valinato; y tetrahidro-2H-piran-4-il(1-hidroxi-7-metil-1,3-dihidrobenzo[c] [1,2]oxaborol-6-carbonilo)-L-valinato. Dichos compuestos son utiles para el tratamiento de enfermedades relacionadas con parasitos, tales como la tripanosomiasis animal africana
PE2019000887A 2016-05-12 2017-05-01 Esteres de oxaborol y sus usos PE20191077A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335565P 2016-05-12 2016-05-12
PCT/IB2017/052522 WO2017195069A1 (en) 2016-05-12 2017-05-01 Oxaborole esters and uses thereof

Publications (1)

Publication Number Publication Date
PE20191077A1 true PE20191077A1 (es) 2019-08-20

Family

ID=58699201

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019000887A PE20191077A1 (es) 2016-05-12 2017-05-01 Esteres de oxaborol y sus usos
PE2018002055A PE20190119A1 (es) 2016-05-12 2017-05-01 Esteres de oxaborol y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018002055A PE20190119A1 (es) 2016-05-12 2017-05-01 Esteres de oxaborol y sus usos

Country Status (31)

Country Link
US (4) US10562921B2 (es)
EP (2) EP3455227A1 (es)
JP (2) JP6715957B2 (es)
KR (2) KR102243775B1 (es)
CN (2) CN109503637B (es)
AR (2) AR108450A1 (es)
AU (2) AU2017263785B2 (es)
BR (2) BR122018076188A2 (es)
CA (1) CA3023490C (es)
CL (2) CL2018003187A1 (es)
CO (1) CO2018012077A2 (es)
CR (2) CR20180502A (es)
DK (1) DK3578562T3 (es)
EA (2) EA036661B1 (es)
EC (2) ECSP18091065A (es)
ES (1) ES2882782T3 (es)
HK (1) HK1258717A1 (es)
HU (1) HUE056320T2 (es)
IL (2) IL262453A (es)
MA (1) MA44968A (es)
MX (2) MX2018013743A (es)
NI (2) NI201801171A (es)
NZ (1) NZ746906A (es)
PE (2) PE20191077A1 (es)
PT (1) PT3578562T (es)
SG (1) SG11201809237RA (es)
TN (2) TN2018000351A1 (es)
TW (1) TWI629279B (es)
UA (2) UA120999C2 (es)
UY (2) UY37236A (es)
WO (1) WO2017195069A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
WO2017155879A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
KR102243775B1 (ko) * 2016-05-12 2021-04-22 아나코르 파마슈티칼스 인코포레이티드 옥사보롤 에스터 및 이의 용도
MX2020005464A (es) 2017-11-30 2020-12-03 Boragen Inc Compuestos de benzoxaborol y formulaciones de los mismos.
JP2020180170A (ja) * 2019-04-23 2020-11-05 東ソー株式会社 ハロゲン含有ポリエーテルポリオール組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
WO2010045503A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
WO2011019618A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
ES2582471T3 (es) 2011-02-07 2016-09-13 Rempex Pharmaceuticals, Inc. Inhibidores polibásicos de la bomba de flujo de salida bacteriana que contienen boro y usos terapéuticos de los mismos
BR112014008186A2 (pt) 2011-10-07 2017-04-11 Syngenta Participations Ag método para proteção de plantas úteis ou material de propagação de plantas
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US8669207B1 (en) * 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
WO2015013318A1 (en) 2013-07-22 2015-01-29 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN105492388B (zh) 2013-08-09 2018-12-21 葛兰素史克知识产权第二有限公司 三环苯并氧杂硼杂环戊烯化合物及其用途
EP3086645A1 (en) 2013-12-23 2016-11-02 Syngenta Participations AG Benzoxaborole fungicides
US20180244699A1 (en) * 2015-08-17 2018-08-30 Syngenta Participations Ag 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides
KR102243775B1 (ko) * 2016-05-12 2021-04-22 아나코르 파마슈티칼스 인코포레이티드 옥사보롤 에스터 및 이의 용도

Also Published As

Publication number Publication date
MX2018015410A (es) 2019-05-27
TWI629279B (zh) 2018-07-11
CL2018003187A1 (es) 2019-01-11
US20210101916A1 (en) 2021-04-08
DK3578562T3 (da) 2021-07-12
KR102231489B1 (ko) 2021-03-23
KR20190002695A (ko) 2019-01-08
US20200017531A1 (en) 2020-01-16
US10882872B2 (en) 2021-01-05
HUE056320T2 (hu) 2022-02-28
JP2019081770A (ja) 2019-05-30
SG11201809237RA (en) 2018-11-29
ECSP18091065A (es) 2019-07-31
UA121354C2 (uk) 2020-05-12
US20170327519A1 (en) 2017-11-16
UY37236A (es) 2018-01-02
UY37980A (es) 2020-06-30
IL262453A (en) 2018-12-31
IL263161B (en) 2022-05-01
CN109153688A (zh) 2019-01-04
NZ746906A (en) 2020-06-26
AU2018264116B2 (en) 2020-03-12
PT3578562T (pt) 2021-08-05
MX2018013743A (es) 2019-05-02
CR20180560A (es) 2019-01-25
AU2017263785A1 (en) 2018-10-25
PE20190119A1 (es) 2019-01-17
TN2018000351A1 (en) 2020-06-15
TN2019000106A1 (en) 2020-10-05
EA036661B1 (ru) 2020-12-04
CA3023490A1 (en) 2017-11-16
BR122018076188A2 (pt) 2019-09-10
EP3455227A1 (en) 2019-03-20
CN109503637B (zh) 2021-03-16
EA201892475A1 (ru) 2019-04-30
HK1258717A1 (zh) 2019-11-15
CA3023490C (en) 2021-06-08
TW201808968A (zh) 2018-03-16
KR20190005982A (ko) 2019-01-16
NI201801171A (es) 2019-04-10
ECSP19026702A (es) 2019-06-30
CO2018012077A2 (es) 2018-11-22
MA44968A (fr) 2019-03-20
ES2882782T3 (es) 2021-12-02
CN109503637A (zh) 2019-03-22
WO2017195069A1 (en) 2017-11-16
US10562921B2 (en) 2020-02-18
AR108450A1 (es) 2018-08-22
AR113543A2 (es) 2020-05-13
CR20180502A (es) 2018-12-21
JP6715957B2 (ja) 2020-07-01
EP3578562A1 (en) 2019-12-11
JP2019520326A (ja) 2019-07-18
US11578087B2 (en) 2023-02-14
JP6715966B2 (ja) 2020-07-01
KR102243775B1 (ko) 2021-04-22
EP3578562B1 (en) 2021-06-23
BR122023022427A2 (pt) 2023-12-26
AU2017263785B2 (en) 2019-10-03
NI201801172A (es) 2019-04-10
AU2018264116A1 (en) 2018-12-06
CL2018003377A1 (es) 2019-01-11
IL263161A (en) 2018-12-31
BR112018071931A2 (pt) 2019-02-05
UA120999C2 (uk) 2020-03-10
EA034415B1 (ru) 2020-02-05
EA201892203A1 (ru) 2019-04-30
US20230132298A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
PE20191077A1 (es) Esteres de oxaborol y sus usos
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2015002361A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
NI201600129A (es) Inhibidores de diacilglicerol aciltransferasa 2
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
NI201800112A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6- (trifluorometil)piridin-2-carboxamida
BR112019025388A2 (pt) Suplemento de ração animal, composição de ração animal, usos de um suplemento de ração animal, métodos para produzir um suplemento de ração animal e para produzir uma composição de ração animal
CO2018004473A2 (es) Compuestos agonistas de ppar y composiciones farmaceuticas
ZA201701844B (en) Antibody capable of neutralizing substance having activity alternative to function of coagulation factor viii (fviii)
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
DK3271015T3 (da) Nk-3-receptorantagonister til terapeutisk eller kosmetisk behandling af overskydende kropsfedt
LT3097085T (lt) Benzoksazinono dariniai, skirti odos ligų gydymui
HUE056094T2 (hu) Növénybetegség elleni szerek felhasználása
DK3402537T3 (da) Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
FR3052669B1 (fr) Prothese biologique destinee au traitement des hernies parastomales
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
SG11201705655TA (en) Process for restoring responsiveness to medication in tissue of living organisms
ITUB20153642A1 (it) Protesi biologica funzionale per il trattamento del prolasso del pavimento pelvico
ITUA20162607A1 (it) Composizione attiva per il trattamento degli olivi
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis
PE20170200A1 (es) Composicion farmaceutica que combina un anticonvulsivante y un derivado del acido nicotinico